Detection of minimal residual disease in multiple myeloma and acute leukaemia.
The importance of minimal residual disease detection has increased due to the advanced therapeutic protocols available for multiple myeloma and acute leukaemia. High-dose chemotherapy, followed by stem cell transplantation is often used in patients with multiple myeloma. But despite a longer disease-free period and overall survival, all patients relapse. In the treatment of acute leukaemia, there are similar problems. The present strategy is to give continuous chemotherapy to eradicate minimal residual disease. In this review, we consider the methods used to detect and quantify minimal residual disease. At present, the most effective seem to be those based on the use of polymerase chain reactions to detect the malignant cells.
Bakkus
M H
MH
Department of Hematology-Immunology, Medical School, Vrije Universiteit Brussel, Belgium. mbakkus@heim.vub.ac.be
Juge-Morineau
N
N
van der Werff ten Bosch
J E
JE
D000208:Acute Disease; D000483:Alleles; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007938:Leukemia / Q000235:genetics*; D009101:Multiple Myeloma / Q000235:genetics*; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods*